AstraZeneca completes Symbicort SMART MRP

15 October 2006

Anglo-Swedish drug major AstraZeneca says that it has successfully completed the European Union Mutual Recognition Procedure for Symbicort (budesonide/formoterol) Maintenance And Reliever Therapy (SMART).

The product, which is licensed for use by adults who require combined corticosteroid and brochodilator treatment, is designed to address both symptom relief and disease maintenance. The firm added that it anticipates that national approvals across the EU will be issued in the coming months.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight